TITLE

Risk factors for early death in patients undergoing treatment for multiple myeloma

AUTHOR(S)
Murakami, H.; Hayashi, K.; Hatsumi, N.; Saitoh, T.; Yokohama, A.; Matsushima, T.; Tsukamoto, N.; Morita, K.; Karasawa, M.; Ogawara, H.; Sawamura, M.; Nojima, Y.
PUB. DATE
August 2001
SOURCE
Annals of Hematology;Aug2001, Vol. 80 Issue 8, p452
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The survival time of myeloma patients improved from a few months to many years after treatment with melphalan. Perhaps chemotherapy more intensive than melphalan-prednisolone should be administered to patients at risk of early death. Therefore, early death must be accurately predicted. We analyzed 93 patients with recently diagnosed myeloma and found that 13 (14%) died within 6 months (early death). The most common cause of death was bacterial and fungal pneumonia when myeloma became uncontrollable. The response to conventional chemotherapy was poorer in patients at high risk of early death than the control group. Multivariate analysis showed that the serum level of beta-2 microglobulin was the only value that predicted early death.
ACCESSION #
15684770

 

Related Articles

  • Extramedullary progression of multiple myeloma despite a good response in the bone marrow in a patient following autologous stem cell transplantation. Kose, Mustafa; Sonnez, Mehmet; Cobanoglu, Umit; Yilmaz, Mustafa; Karti, S. Sami; Ovali, Ercument; Ozoran, Yavuz // Turkish Journal of Cancer;Apr2003, Vol. 33 Issue 2, p102 

    Extramedullary plasmacytomas may be seen in the course of multiple myeloma. However, extramedullary progression despite good response in the bone marrow to therapy is extremely rare. Recently, two cases of multiple with extramedullary progression despite continued response to thalidomide in the...

  • Cure of multiple myeloma – more hype, less reality. Hari, P.; Pasquini, M. C.; Vesole, D. H. // Bone Marrow Transplantation;Jan2006, Vol. 37 Issue 1, p1 

    Randomized studies have firmly established the role of autologous transplant as initial therapy in multiple myeloma (MM). Indeed, MM has emerged as the commonest indication for autologous SCT in North America. The conceptual basis for high-dose therapy is the goal of complete remission (CR)...

  • Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways. Kobayashi, T.; Kuroda, J.; Ashihara, E.; Oomizu, S.; Terui, Y.; Taniyama, A.; Adachi, S.; Takagi, T.; Yamamoto, M.; Sasaki, N.; Horiike, S.; Hatake, K.; Yamauchi, A.; Hirashima, M.; Taniwaki, M. // Leukemia (08876924);Apr2010, Vol. 24 Issue 4, p843 

    Galectins constitute a family of lectins that specifically exhibit the affinity for β-galactosides and modulate various biological events. Galectin-9 is a tandem-repeat type galectin with two carbohydrate recognition domains and has recently been shown to have an anti-proliferative effect on...

  • Cytostatic and Cytocidal Effects of Mistletoe (Viscum album L.) Quercus Extract Iscador. Kovacs, Eva; Link, Susanne; Toffol-Schmidt, Ulrike // Drug Research / Arzneimittel-Forschung (Editio Cantor Verlag fur;Jun2006, Vol. 56 Issue 6, p467 

    Mistletoe (Viscum album) extract (Iscador®) is used either alone or in combination with chemotherapy or radiotherapy in the treatment of tumor patients. In this study the effects of Viscum album Quercus (VA Qu) extract (1000 ng lectin and 6 μg viscotoxin/ml) in various doses were...

  • Reduced-intensity conditioning 2/Tolerance and rejection.  // Bone Marrow Transplantation;Mar2005 Supplement 2, Vol. 35, p69 

    The article focuses on reduced-intensity conditioning. Increasing patient age is a well-established risk factor for the outcome of allogeneic hematopoietic stem cell transplantation. It is generally assumed that patients aged 50 years or older are candidates for reduced-intensity conditioning...

  • The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. R. García-Sanz Jr.; González-Porras; Hernández, J. M.; Polo-zarzuela, M.; Sureda, A.; Barrenetxea, C.; Palomera, L.; López, R.; Grande-García, C.; Alegre, A.; Vargas-Pabón, M.; Gutiérrez, O. N.; Rodríguez, J. A.; Miguel, J. F.San // Leukemia (08876924);Apr2004, Vol. 18 Issue 4, p856 

    We evaluate the efficacy of the oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) in 71 refractory/relapsed multiple myeloma patients, including a prognostic analysis to predict both response and survival. Patients received thalidomide at escalating doses (200-800...

  • Treatment of MM-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy. Yang, Zuozhang; Tan, Jing; Xu, Yongqing; Sun, Hongpu; Xie, Lin; Zhao, Ruilian; Wang, Jiaping; Jiang, Hua // European Spine Journal;May2012, Vol. 21 Issue 5, p912 

    Purpose: To investigate the effect of treatment of multiple myeloma (MM)-associated spinal fracture with percutaneous vertebroplasty (PVP) and chemotherapy. Methods: Patients with MM-associated spinal fracture were randomly divided into combined (PVP and chemotherapy) treatment group ( n = 38)...

  • Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies. Gopalakrishnan, Sathish; Tan, Daryl // Blood & Lymphatic Cancer: Targets & Therapy;2013, Vol. 3, p19 

    Although the clinical outcomes of patients with multiple myeloma has improved tremendously with the advent of bortezomib and immunomodulatory drugs like thalidomide and lenalidomide, the disease remains incurable and patients will eventually be resistant to these drugs. Novel non-cross-resistant...

  • New Treatment Strategies for Multiple Myeloma by Targeting BCL-2 and the Mevalonate Pathway. van de Donk, Niels W. C. J.; Bloem, Andries C.; Spek, Ellen v. d.; Lokhorst, Henk M. // Current Pharmaceutical Design;Jan2006, Vol. 12 Issue 3, p327 

    Insight into the mechanisms of primary or acquired drug resistance of (hematological) malignancies is critical for the development of new treatment strategies. This review will focus on Bcl-2 and the mevalonate pathway as targets for reversal of drug resistance in multiple myeloma. The Bcl-2...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics